| 1 |
0.9% normal saline (control) |
- |
- |
- |
- |
299 [1] 299 💬 |
| 2 |
Active control |
- |
- |
- |
- |
013 [1] 13 💬 |
| 3 |
Amitriptyline, fluoxetine and tramadol alone (control group) |
Amitriptyline |
[6] D00326 D00326, D00809 D00809, D00823 D00823, D01355 D01355, D07448 D07448, D08623 D08623 💬 |
OPRM1 [3] OPRM1, SLC6A2, SLC6A4 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
078 [1] 78 💬 |
| 4 |
Behavioral: assessment of severity of icd (impulse control disorders) |
- |
- |
- |
- |
006 [1] 6 💬 |
| 5 |
Behavioral: attention control |
- |
- |
- |
- |
006 [1] 6 💬 |
| 6 |
Behavioral: healthy age-matched controls |
- |
- |
- |
- |
006 [1] 6 💬 |
| 7 |
Behavioral: low-impact exercise control |
- |
- |
- |
- |
006 [1] 6 💬 |
| 8 |
Behavioral: protein and calorie controlled diet |
- |
- |
- |
- |
251 [1] 251 💬 |
| 9 |
Boots high strength garlic odour controlled |
Garlic |
- |
- |
- |
299 [1] 299 💬 |
| 10 |
Bpr277 ointment (controlled application) |
- |
- |
- |
- |
160 [1] 160 💬 |
| 11 |
Coenzyme q-10 in normal control subjects |
Ubidecarenone |
[1] D01065 D01065 💬 |
- |
- |
086 [1] 86 💬 |
| 12 |
Control |
- |
- |
- |
- |
006 [4] 6 , 46, 168, 299 💬 |
| 13 |
Control group |
- |
- |
- |
- |
002 [3] 2 , 46, 70 💬 |
| 14 |
Control group 0.9% isotonic saline |
- |
- |
- |
- |
299 [1] 299 💬 |
| 15 |
Control intervention (no dexamethasone) |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
| 16 |
Control multivitamin |
- |
- |
- |
- |
299 [1] 299 💬 |
| 17 |
Controlled-release levodopa / carbidopa |
Carbidopa |
[2] D00059 D00059, D00558 D00558 💬 |
DDC [6] DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism [16] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 [1] 6 💬 |
| 18 |
Cornstarch control |
Starch, corn |
[1] D05297 D05297 💬 |
- |
- |
090 [1] 90 💬 |
| 19 |
Diagnostic test: blood drawing in healthy controls |
- |
- |
- |
- |
065 [1] 65 💬 |
| 20 |
Diazoxide choline controlled-release tablet |
Choline |
[2] D00294 D00294, D07690 D07690 💬 |
ABCC8 [2] ABCC8, KCNJ11 💬 |
ABC transporters [4] ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus |
193 [1] 193 💬 |
| 21 |
Epilim chrono 200 controlled released tablets |
- |
- |
- |
- |
256 [1] 256 💬 |
| 22 |
Epilim chrono 300 controlled released tablets |
- |
- |
- |
- |
256 [1] 256 💬 |
| 23 |
Epilim chrono 500 controlled released tablets |
- |
- |
- |
- |
256 [1] 256 💬 |
| 24 |
Group 1- control diet |
- |
- |
- |
- |
097 [1] 97 💬 |
| 25 |
High dose vehicle control |
- |
- |
- |
- |
046 [1] 46 💬 |
| 26 |
Histamine |
Histamine |
[1] D08040 D08040 💬 |
HRH1 [4] HRH1, HRH2, HRH3, HRH4 💬 |
Calcium signaling pathway [4] Calcium signaling pathway, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
| 27 |
Infliximab control |
Infliximab |
[1] D02598 D02598 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [1] 46 💬 |
| 28 |
Levodopa cr (controlled release) |
Levodopa |
[1] D00059 D00059 💬 |
DRD1 [5] DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism [11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
| 29 |
Low dose vehicle control |
- |
- |
- |
- |
046 [1] 46 💬 |
| 30 |
Other: control |
- |
- |
- |
- |
006 [8] 6 , 19, 70, 75, 85, 97, 162, 193 💬 |
| 31 |
Other: control diet |
- |
- |
- |
- |
096 [1] 96 💬 |
| 32 |
Other: control group |
- |
- |
- |
- |
002 [1] 2 💬 |
| 33 |
Other: control group(normal saline) |
- |
- |
- |
- |
097 [1] 97 💬 |
| 34 |
Other: control wound treatment |
- |
- |
- |
- |
036 [1] 36 💬 |
| 35 |
Other: controlled environment tests (series of tasks of everyday life) |
- |
- |
- |
- |
006 [1] 6 💬 |
| 36 |
Other: controls primary cervical dystonia (trihexyphenidyl) |
Trihexyphenidyl |
[2] D00787 D00787, D08638 D08638 💬 |
CHRM1 [5] CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease [13] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 [1] 6 💬 |
| 37 |
Other: dyt 1 dystonia (healthy control) |
- |
- |
- |
- |
006 [1] 6 💬 |
| 38 |
Other: healthy controls |
- |
- |
- |
- |
063 [1] 63 💬 |
| 39 |
Other: histamine |
Histamine |
[1] D08040 D08040 💬 |
HRH1 [4] HRH1, HRH2, HRH3, HRH4 💬 |
Calcium signaling pathway [4] Calcium signaling pathway, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
| 40 |
Other: historical control |
- |
- |
- |
- |
002 [1] 2 💬 |
| 41 |
Other: low blood pressure control |
- |
- |
- |
- |
067 [1] 67 💬 |
| 42 |
Other: no msdmds therapy (control) |
- |
- |
- |
- |
013 [1] 13 💬 |
| 43 |
Other: normal (control) diet |
- |
- |
- |
- |
240 [1] 240 💬 |
| 44 |
Other: observational control |
- |
- |
- |
- |
013 [1] 13 💬 |
| 45 |
Other: reaction time and postural control |
- |
- |
- |
- |
299 [1] 299 💬 |
| 46 |
Other: standard blood pressure control |
- |
- |
- |
- |
067 [1] 67 💬 |
| 47 |
Oxycodone by patient-controlled analgesia (pca) |
Oxycodone |
[3] D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
046 [1] 46 💬 |
| 48 |
Procedure: control group |
- |
- |
- |
- |
034 [1] 34 💬 |
| 49 |
Ropinirole controlled-release (requip cr) for rls |
Ropinirole |
[2] D00784 D00784, D08489 D08489 💬 |
DRD2 [3] DRD2, DRD3, DRD4 💬 |
Alcoholism [8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
| 50 |
Sinemet® controlled release (carbidopa/levodopa) |
Carbidopa |
[2] D00059 D00059, D00558 D00558 💬 |
DDC [6] DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism [16] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 [1] 6 💬 |
| 51 |
Vehice control |
- |
- |
- |
- |
096 [1] 96 💬 |
| 52 |
Vehicle control |
- |
- |
- |
- |
053 [1] 53 💬 |